LBRX
LB Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
8.52 / 10
Outperform
Analyst consensus is a Strong Buy (100%) from a single Stifel analyst, with a weighted rating of 9.24. Fund‑flow score 7.79 indicates strong inflows across most investor sizes. JPMorgan’s recent 1.03 M‑share purchase reinforces bullish sentiment.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-27
InstitutionStifel
Times predicted3
Historical Win Rate66.7%
What is the analyst consensus for LBRX?
- LBRX holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 8.52/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
